Circulating Ang-2 mRNA Expression Levels: Looking Ahead to a New Prognostic Factor for NSCLC

• Ana L. Coelho ,

  * E-mail: pequenocoelho@hotmail.com

  Affiliations Molecular Oncology Group, Portuguese Institute of Oncology Porto, Porto, Portugal, Faculty of Medicine, University of Porto, Porto, Portugal

  ⨯
• António Araújo,

  Affiliations Molecular Oncology Group, Portuguese Institute of Oncology Porto, Porto, Portugal, Medical Oncology Department, Centro Hospitalar de Entre o Douro e Vouga, Santa Maria da Feira, Portugal, Abel Salazar Institute for the Biomedical Sciences, University of Porto, Porto, Portugal

  ⨯
• Mónica Gomes,

  Affiliations Molecular Oncology Group, Portuguese Institute of Oncology Porto, Porto, Portugal, Abel Salazar Institute for the Biomedical Sciences, University of Porto, Porto, Portugal

  ⨯
• Raquel Catarino,

  Affiliations Molecular Oncology Group, Portuguese Institute of Oncology Porto, Porto, Portugal, Abel Salazar Institute for the Biomedical Sciences, University of Porto, Porto, Portugal

  ⨯
• Agostinho Marques,

  Affiliations Faculty of Medicine, University of Porto, Porto, Portugal, Pulmonology Department, Centro Hospitalar de S. João, Porto, Portugal

  ⨯
• Rui Medeiros

  Affiliations Molecular Oncology Group, Portuguese Institute of Oncology Porto, Porto, Portugal, Abel Salazar Institute for the Biomedical Sciences, University of Porto, Porto, Portugal, Research Department, Portuguese League Against Cancer (NRNorte), Porto, Portugal

  ⨯